February 10, 2020 Clinical Research/Diagn. Mass Spectrometry

Fluidigm Establishes Center of Excellence at NCI-Designated Comprehensive Cancer Center to Advance Imaging Mass Cytometry

New Center of Excellence to Advance Highly Multiplexed Tissue Imaging in Translational and Clinical Cancer Research SOUTH SAN FRANCISCO, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will establish a new Center of Excellence (CoE) for Imaging Mass Cytometry™ at Georgetown... Read more

February 3, 2020 Clinical Research/Diagn. Product Launch

QIAGEN launches FFPE and Liquid Biopsy PIK3CA diagnostics in Europe to enhance precision medicine in advanced breast cancer

Germantown, Maryland, and Hilden, Germany, February 3, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the CE-marking and launch of its therascreen® PIK3CA RGQ PCR Kit in Europe as an aid in identifying breast cancer patients with a PIK3CA mutation. Last year the therascreen PIK3CA test was approved by the FDA... Read more

January 30, 2020 Clinical Research/Diagn. Lab Top-10

Agilent Teams with Indian Institute of Technology Delhi to Enhance Biotherapeutics

Agilent Teams with Indian Institute of Technology Delhi to Enhance Biotherapeutics Agilent and IIT Delhi to set up incubator site for bioanalytical science SANTA CLARA, Calif , January 29, 2020 Agilent Technologies Inc. (NYSE: A) today announced that it is joining forces with the Indian Institute of Technology Delhi (IIT Delhi) to promote biopharmaceutical research.... Read more

January 21, 2020 Clinical Research/Diagn. M&A, Partnerships

Three Industry Leaders Form New Venture to Create Scalable Manufacturing Platforms for Cell and Gene Therapies

JANUARY 21, 2020 MIAMI, Fla., January 21, 2020 – Bio-Techne, Fresenius Kabi, and Wilson Wolf have formed a new joint venture company to provide dedicated support to researchers and biopharmaceutical companies in the field of cell and gene therapy. The joint venture will focus on providing scalable manufacturing technologies and processes needed to develop and commercialize... Read more

January 21, 2020 Clinical Research/Diagn.

Takara Bio Launches a New Facility for the Research and Manufacturing of Regenerative Medicine Products

2020/01/21 Kusatsu/Shiga Japan – January 21, 2020 – Takara Bio Inc. (Takara Bio), announced completion of a new facility, the Center for Gene and Cell Processing II (new facility) for the research and manufacturing of regenerative medicine products in Kusatsu, Shiga and operation start since January 2020.   Takara Bio constructed a Center for Gene... Read more

January 17, 2020 Clinical Research/Diagn. M&A, Partnerships Mass Spectrometry

Shimadzu and Providence Cancer Institute Partner to Advance Cancer Immunotherapy Research

Jan 17, 2020 Shimadzu Corporation and the Earle A. Chiles Research Institute, a division of Providence Cancer Institute (Providence) in Portland, Oregon, have entered into a joint research agreement to apply mass spectrometry technology to develop tools for personalized cancer immunotherapeutics. Shimadzu and Providence will develop technologies to reliably identify cancer antigens recognized by an... Read more

January 16, 2020 Clinical Research/Diagn. Other Lab Products/Services Product Launch

QIAGEN launches Oncology Molecular Profiling Services in Europe

Redwood City, California, and Hilden, Germany, January 15, 2020 – QIAGEN today announced the launch of QCI Precision Insights in Europe, with the inclusion of the European Society for Medical Oncology (ESMO) guidelines and European Medicines Agency (EMA) approved oncology drugs catalogue. QCI Precision Insights is a clinical interpretation service provided by a team of molecular... Read more

January 15, 2020 Clinical Research/Diagn. Product Launch

Roche helps further reduce risk of severe illness for transplant patients by expanding the portfolio to include Adenovirus Test on the cobas 6800/8800 Systems

●  Immunocompromised transplant recipients are at risk of major complications when infected with adenovirus, a common and highly contagious virus ●  Healthcare professionals can use this new test to determine whether transplant patients are at risk of developing severe illness from adenovirus infection ●  The Adenovirus Test leverages the flexibility, automation, and reliability of the cobas omni Utility... Read more

January 14, 2020 Clinical Research/Diagn. Licensing, IP, and Legal Life Science Tools

Advanced BioMatrix Acquires HyStem® from Lineage Cell Therapeutics

Advanced BioMatrix acquires HyStem® technology for R&D marketTechnology highly synergistic with existing Advanced BioMatrix productsAdvanced BioMatrix to fully manufacture and distribute the HyStem® kits California, USA – January 14, 2020 – Advanced BioMatrix has acquired the HyStem® line of products from Lineage Cell Therapeutics – previously BioTime/ESI Bio/Glycosan. HyStem® kits are based on innovative thiolated hyaluronic... Read more

January 14, 2020 Clinical Research/Diagn. Life Science Tools M&A, Partnerships

LabCorp to Adopt Thermo Fisher Scientific’s Ion Torrent Genexus Next-Generation Sequencing System and Pan-Cancer Assay for Use in Oncology Research and Development

January 14, 2020 06:39 AM Eastern Standard Time BURLINGTON, N.C. & CARLSBAD, Calif.–(BUSINESS WIRE)–LabCorp® (NYSE: LH) announced it will adopt the Ion Torrent Genexus System* and Oncomine Precision Assay* for use in research and development of companion diagnostics as well as other future oncology and precision medicine applications. LabCorp will also evaluate the potential for... Read more